The association of fibroblast growth factor 23 at mid-life and late-life with subsequent risk of cardiovascular disease: The Atherosclerosis Risk in Communities (ARIC) Study-Reference-Cited by-同舟云学术

The association of fibroblast growth factor 23 at mid-life and late-life with subsequent risk of cardiovascular disease: The Atherosclerosis Risk in Communities (ARIC) Study

Published:2022-01 Issue: Volume:13 Page:100124
ISSN:2666-6022
Container-title:American Heart Journal Plus: Cardiology Research and Practice
language:en
Short-container-title:American Heart Journal Plus: Cardiology Research and Practice

Author:

Honda Yasuyuki,Ishigami Junichi,Karger Amy B.,Coresh Josef,Selvin Elizabeth,Lutsey Pamela L.,Matsushita Kunihiro

Funder

National Heart Lung and Blood Institute

Publisher

Elsevier BV

Subject

General Medicine

Reference42 articles.

1. Serum FGF23 levels in normal and disordered phosphorus homeostasis;Weber;J. Bone Miner. Res.,2003

2. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4;Seiler;Clin. J. Am. Soc. Nephrol.,2014

3. Fibroblast growth factor-23 and cardiovascular events in CKD;Scialla;J. Am. Soc. Nephrol.,2014

4. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular health Study);Ix;J. Am. Coll. Cardiol.,2012

5. Fibroblast growth factor-23 and cardiovascular disease in the general population: the multi-ethnic study of atherosclerosis;Kestenbaum;Circ. Heart Fail.,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum FGF-23 and klotho levels in patients with systemic sclerosis and its relationship with carotid intima media thickness;Annals of Clinical and Analytical Medicine;2024